In the world economic growth, the BCG Vaccine Industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, BCG Vaccine market size to maintain the average annual growth rate of XXX from XXX million $ in 2014 to XXX million $ in 2019, SMI analysts believe that in the next few years, BCG Vaccine market size will be further expanded, we expect that by 2024, The market size of the BCG Vaccine will reach XXX million $.
Bacillus Calmette–Guérin (BCG) vaccine is a vaccine primarily used against tuberculosis (TB). BCG is prepared from Mycobacterium Bovis, a slow-growing aerobic bacterium and the causative agent of TB in cattle.
High incidence of TB is expected to propel growth of the global BCG vaccine market over the forecast period. For instance, according to the World Health Organization, in 2018, the incidence of TB in India was 2.69 million cases. Moreover, increasing prevalence of non-tuberculous mycobacterial (NTM) infections is also expected to aid in growth of the market. For instance, according to the study, “Epidemiology of Nontuberculous Mycobacterial Infection, South Korea, 2007–2016”, published in the journal Emerging Infectious Diseases, in March 2019, the prevalence and incidence of NTM infections in South Korea increased to 39.6 cases/100,000 population in 2016 and annual incidence to 19.0 cases/100,000 population during 2007-2016.
Increasing adoption of BCG is the treatment of bladder cancer is expected to offer lucrative growth opportunities for players in the market. According to the National Cancer Institute, the U.S. is expected to record 81,400 new cases of bladder cancer in 2020. Moreover, R&D BCG vaccines are also expected to aid in growth of the market. For instance, in February 2020, researchers from Pontificia Universidad Católica de Chile, Chile, reported the development of a recombinant BCG vaccine expressing the nucleoprotein of the human respiratory syncytial virus.
However, BCG immunization is expected to cause some side effects such as, swollen lymph nodes, small red areas at the site of injection, fever, and blood in the urine, which are expected to limit growth of the global BCG vaccine market.
Key Takeaways:
- The use of genetically-modified BCG vaccines for the treatment of COVID-19 is expected to offer a conducive environment for growth of the global BCG vaccine market. For instance, in March 2020, in the U.S., the Faustman Lab announced a clinical trial that will assess the efficacy of BCG's potential in the protection against COVID-19.
- Major players in the market are focused on expanding their production capabilities to enhance their market share. For instance, in September 2019, Serum Institute of India Pvt. Ltd. started a new plant in Pune, India.
- Major players in the market are also focused on adopting collaboration strategies to expand their product portfolio. For instance, in April 2020, Sanofi Pasteur collaborated with GSK to develop an adjuvanted vaccine for COVID-19.
- Major players operating in the market include Merck, Sanofi Pasteur, Evans Vaccines Ltd. (Pfizer Inc.), Japan BCG Laboratory, China National Biotec Group Company, Serum Institute of India Pvt. Ltd., Intervax Ltd., and GreenSignal Bio Pharma Private Limited
This Report covers the manufacturers' data, including: shipment, price, revenue, gross profit, interview record, business distribution, etc., these data help the consumer know about the competitors better. This report also covers all the regions and countries of the world, which shows a regional development status, including market size, volume and value, as well as price data.
Besides, the report also covers segment data, including: type segment, industry segment, channel segment, etc. cover different segment market sizes, both volume, and value. Also cover different industries client's information, which is very important for the manufacturers. If you need more information, please contact SMI
Section 1: Definition
Section (2 3): Manufacturer Detail
✑ Merck
✑ Sanofi Pasteur
✑ Japan BCG Lab
✑ China National Biotec
✑ Serum Institute of India
✑ Intervax
✑ GSBPL
Section 4: Region Segmentation
✑ North America Country (United States, Canada)
✑ South America
✑ Asia Country (China, Japan, India, Korea)
✑ Europe Country (Germany, UK, France, Italy)
✑ Other Country (Middle East, Africa, GCC)
Section (5 6 7): Segmentation
Product Type Segmentation -
✑ Immune BCG
✑ Therapy BCG
Industry Segmentation -
✑ Hospitals
✑ Clinics
Channel (Direct Sales, Distributor) Segmentation
Section 8: Trend (2019-2024)
Section 9: Product Type Detail
Section 10: Downstream Consumer
Section 11: Cost Structure
Section 12: Conclusion
Request Discount 
Inquire Before Buy
